SeqLL, Inc. Files Amendment 10 to S-1 Registration Statement
Ticker: SQLLW · Form: S-1/A · Filed: Jan 17, 2024 · CIK: 1605888
| Field | Detail |
|---|---|
| Company | Seqll, Inc. (SQLLW) |
| Form Type | S-1/A |
| Filed Date | Jan 17, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $20,000,000, $0.00001, $13.00, $20.00, $10.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: IPO, S-1 Filing, Securities Registration, SeqLL Inc., SEC Filing
TL;DR
<b>SeqLL, Inc. has filed its 10th amendment to its S-1 registration statement, indicating ongoing preparations for a public securities offering.</b>
AI Summary
SeqLL, Inc. (SQLLW) filed a Amended IPO Registration (S-1/A) with the SEC on January 17, 2024. SeqLL, Inc. filed Amendment No. 10 to its Form S-1 Registration Statement with the SEC on January 17, 2024. The filing is related to the registration of securities under the Securities Act of 1933. The company's principal executive offices are located at 3 Federal Street, Billerica, MA 01821. The filing indicates that the securities may be offered on a delayed or continuous basis pursuant to Rule 415. The registration statement number is 333-272908.
Why It Matters
For investors and stakeholders tracking SeqLL, Inc., this filing contains several important signals. This amendment signifies continued progress in SeqLL's efforts to go public or raise capital through the sale of securities. The filing provides updated information and legal disclosures required for a public offering, impacting potential investors and regulatory oversight.
Risk Assessment
Risk Level: low — SeqLL, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies preparing for an IPO or other public offering, and does not contain new financial performance data or significant business changes.
Analyst Insight
Monitor future filings for updated financial information and details regarding the proposed offering, such as the number of shares and pricing, to assess investment potential.
Key Numbers
- 10 — Amendment Number (Amendment No. 10 to Form S-1 Registration Statement)
- 333-272908 — Registration Number (Registration No. 333-272908)
- 2024-01-17 — Filing Date (Filed on January 17, 2024)
- 1933 — Securities Act Year (Under the Securities Act of 1933)
Key Players & Entities
- SeqLL, Inc. (company) — Registrant name
- 333-272908 (regulator) — Registration number
- January 17, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 3 Federal Street Billerica, MA 01821 (address) — Principal executive offices
- Daniel Jones (person) — Chief Executive Officer
- Pryor Cashman LLP (company) — Legal counsel
- Loeb & Loeb LLP (company) — Legal counsel
Forward-Looking Statements
- SeqLL, Inc. will complete its public offering within the next 6 months. (SeqLL, Inc.) — medium confidence, target: 2024-07-17
FAQ
When did SeqLL, Inc. file this S-1/A?
SeqLL, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on January 17, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by SeqLL, Inc. (SQLLW).
Where can I read the original S-1/A filing from SeqLL, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SeqLL, Inc..
What are the key takeaways from SeqLL, Inc.'s S-1/A?
SeqLL, Inc. filed this S-1/A on January 17, 2024. Key takeaways: SeqLL, Inc. filed Amendment No. 10 to its Form S-1 Registration Statement with the SEC on January 17, 2024.. The filing is related to the registration of securities under the Securities Act of 1933.. The company's principal executive offices are located at 3 Federal Street, Billerica, MA 01821..
Is SeqLL, Inc. a risky investment based on this filing?
Based on this S-1/A, SeqLL, Inc. presents a relatively low-risk profile. The filing is an amendment to a registration statement, which is a standard procedural step for companies preparing for an IPO or other public offering, and does not contain new financial performance data or significant business changes.
What should investors do after reading SeqLL, Inc.'s S-1/A?
Monitor future filings for updated financial information and details regarding the proposed offering, such as the number of shares and pricing, to assess investment potential. The overall sentiment from this filing is neutral.
How does SeqLL, Inc. compare to its industry peers?
The filing pertains to the process of registering securities for public offering, a common step for companies seeking to raise capital or become publicly traded.
Are there regulatory concerns for SeqLL, Inc.?
The filing is made under the Securities Act of 1933, which governs the registration and disclosure requirements for public offerings of securities in the United States.
Industry Context
The filing pertains to the process of registering securities for public offering, a common step for companies seeking to raise capital or become publicly traded.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration and disclosure requirements for public offerings of securities in the United States.
What Investors Should Do
- Review the full S-1/A filing for detailed disclosures on the company's business, financials, and the terms of the proposed offering.
- Track subsequent amendments and the eventual effectiveness of the registration statement for updates on the offering.
- Analyze the company's business model and market position once more detailed information becomes available in future filings.
Key Dates
- 2024-01-17: Filing of Amendment No. 10 to Form S-1 — Indicates continued progress in the company's registration process for securities.
Year-Over-Year Comparison
This is Amendment No. 10 to the S-1 registration statement, indicating multiple prior submissions and revisions to the initial filing.
Filing Stats: 4,291 words · 17 min read · ~14 pages · Grade level 15.7 · Accepted 2024-01-16 21:57:23
Key Financial Figures
- $20,000,000 — Y PROSPECTUS (Currently SeqLL Inc.) $20,000,000 2,000,000 Units Each Unit consisting
- $0.00001 — a0;one share of common stock, par value $0.00001 per share; and (ii) one Series A Warran
- $13.00 — is exercisable at an exercise price of $13.00 per share (130% of the offering price p
- $20.00 — is exercisable at an exercise price of $20.00 per share (200% of the offering price p
- $10.00 — at an assumed public offering price of $10.00 per Unit. We are also offering to thos
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
- $0.0001 — of each Pre -Funded Warrant will equal $0.0001 per share of common stock. For each Pre
- $3.50 — last bid price of our common stock was $3.50. The public offering price of the Units
- $3,000,000 — ll receive additional gross proceeds of $3,000,000, less a 7% commission fee to the underw
- $100,000,000 — c believes that multiple targets in the $100,000,000 revenue range are readily available for
Filing Documents
- fs12023a10_seqllinc.htm (S-1/A) — 10070KB
- fs12023a10ex2-6_seqllinc.htm (EX-2.6) — 23KB
- fs12023a10ex4-7_seqllinc.htm (EX-4.7) — 98KB
- fs12023a10ex4-8_seqllinc.htm (EX-4.8) — 98KB
- fs12023a10ex5-1_seqllinc.htm (EX-5.1) — 19KB
- fs12023a10ex10-12_seqllinc.htm (EX-10.12) — 19KB
- fs12023a10ex10-13_seqllinc.htm (EX-10.13) — 30KB
- fs12023a10ex10-14_seqllinc.htm (EX-10.14) — 97KB
- fs12023a10ex10-15_seqllinc.htm (EX-10.15) — 94KB
- fs12023a10ex10-16_seqllinc.htm (EX-10.16) — 83KB
- fs12023a10ex23-1_seqllinc.htm (EX-23.1) — 2KB
- fs12023a10ex23-2_seqllinc.htm (EX-23.2) — 2KB
- fs12023a10ex-fee_seqllinc.htm (EX-FILING FEES) — 110KB
- ex5-1_001.jpg (GRAPHIC) — 8KB
- ex5-1_002.jpg (GRAPHIC) — 3KB
- ex23-2_001.jpg (GRAPHIC) — 5KB
- tatlantic_logo.jpg (GRAPHIC) — 64KB
- tefhutton_logo.jpg (GRAPHIC) — 20KB
- timage_001.jpg (GRAPHIC) — 298KB
- 0001213900-24-003875.txt ( ) — 11294KB
Risk Factors
Risk Factors   14 Cautionary Note Regarding Forward-Looking Statements   36
Use of Proceeds
Use of Proceeds   38 Dividend Policy   39 Capitalization   40 Market for Common Stock and Related Stockholder Matters   42
Dilution
Dilution   43 Management’s Discussion and Analysis of Financial Condition and Results of Operations of Lyneer   45 Our Selected Historical Consolidated Financial Data   64 Unaudited Pro Forma Condensed Combined Financial Information   65 Equivalent and Comparative Per Share Information   76
Business
Business   77 Information About Atlantic   84 Management   86 Compensation of Executive Officers and Directors   92 Certain Relationships and Related Person Transactions   102 Principal Stockholders   104
Description of Capital Stock
Description of Capital Stock   106 Shares Eligible for Future Sale   114
Underwriting
Underwriting   116 Legal Matters   121 Experts   121 Incorporation of Certain Information by Reference   122 Where You Can Find Additional Information   123 Index to Financial Statements   F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under the circumstances and in the jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We have not, and the underwriters have not, authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date of this prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful. For investors outside the United States: We have not, and the underwriters